FDA to Review Abuse-Deterrent Oxycodone Capsule
FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting.... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates adalimumab NSAIDs Oxycodone plaque psoriasis tildrakizumab-asmn Source Type: research
More News: Humira | New Drug Applications | Oxycodone | OxyContin | Psoriasis | Rheumatology | Smokers | Substance Abuse